BioCryst Pharmaceuticals, Inc.

We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema ("HAE") and other rare diseases. The company has a commercial infrastructure for ORLADEYO, an oral, once-daily therapy for the prevention of HAE attacks, which was discovered and developed internally. This commercial platform is leveraged to commercialize a pipeline of potential first-in-class or best-in-class oral small molecule and injectable protein therapeutics for rare diseases, pursued through internal discovery and strategic business development. The company's commercially available or actively developed molecules include: - ORLADEYO® (berotralstat), an Oral Serine Protease Inhibitor Targeting Kallikrein, approved in the United States and multiple global markets as a once-daily oral capsule treatment for Hereditary Angioedema. A once-daily oral pellets treatment for patients 2 to <12 years of age is approved in the United States for Hereditary Angioedema. - Navenibart (STAR-0215), a Monoclonal Antibody Plasma Kallikrein Inhibitor, in Phase 3 for Hereditary Angioedema. - BCX17725, a Protein Therapeutic, in Phase 1 for Netherton Syndrome. - Avoralstat, an Ocular Plasma Kallikrein Inhibitor, in Phase 1 for Diabetic Macular Edema. - STAR-0310, a Monoclonal Antibody OX40 Antagonist, in Phase 1a for Atopic Dermatitis. - RAPIVAB® (peramivir injection), an Intravenous Neuraminidase Inhibitor, approved in the United States, Australia & Canada for Acute Uncomplicated Influenza. - RAPIACTA® (peramivir injection), an Intravenous Neuraminidase Inhibitor, for Uncomplicated... (text truncated). The company is also pursuing certain pre-clinical medicines for other rare disease targets.